Details of the Drug Combination

General Information of Drug Combination (ID: DCLS1J1)

Drug Combination Name
ABIRATERONE Altretamine
Indication
Disease Entry Status REF
High grade ovarian serous adenocarcinoma Investigative [1]
Component Drugs ABIRATERONE   DM8V75C Altretamine   DMKLAYG
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: OVCAR-5
Zero Interaction Potency (ZIP) Score: 2.23
Bliss Independence Score: 5.64
Loewe Additivity Score: 3.21
LHighest Single Agent (HSA) Score: 4.34

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of ABIRATERONE
Disease Entry ICD 11 Status REF
Prostate cancer 2C82.0 Approved [2]
ABIRATERONE Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Steroid 17-alpha-monooxygenase (S17AH) TTRA5BZ CP17A_HUMAN Modulator [4]
------------------------------------------------------------------------------------
Indication(s) of Altretamine
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Approved [3]
Altretamine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Breaker [5]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult T acute lymphoblastic leukemia DC6GVW2 MOLT-4 Investigative [6]
Chronic myelogenous leukemia DCIO3D7 K-562 Investigative [6]
Renal cell carcinoma DCA0EJG SN12C Investigative [6]
Carcinoma DCUHHVN MCF7 Investigative [7]
Invasive ductal carcinoma DC1BJ6Q BT-549 Investigative [7]
Adenocarcinoma DCMMR10 SW-620 Investigative [1]
Amelanotic melanoma DCLT3EP MDA-MB-435 Investigative [1]
Malignant melanoma DCAM5NP LOX IMVI Investigative [1]
Melanoma DC8VMH9 SK-MEL-2 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DrugCom(s)

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6745).
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7112).
4 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
5 Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agen... Cancer Chemother Pharmacol. 2008 Dec;63(1):19-26.
6 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
7 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165